Lifestance Health Group, Inc. Stock Price, News & Analysis

LifeStance Health (LFST) has appointed Vaughn Paunovich as its new Chief Technology Officer, effective June 9, 2025. Paunovich, who brings over 25 years of healthcare technology experience, will lead the company's end-to-end technology strategy. He previously served as EVP, Enterprise Platforms at Amwell and held leadership roles at UnitedHealth Group, including CIO of Optum Health.

Paunovich succeeds Pablo Pantaleoni, who is stepping down after joining in 2020 and leading the company's digital transformation efforts. The new CTO will focus on improving patient and clinician experience, increasing access to mental health services, and implementing scalable technologies aligned with LifeStance's mission of delivering virtual and in-person outpatient mental health care.

National Veterinary Associates (NVA) has announced key board appointments ahead of its planned IPO, naming Ken Burdick as Executive Chairman and Dr. Mike McFarland as Director. Burdick brings over 40 years of healthcare experience and currently serves as Executive Chairman at LifeStance Health (NASDAQ: LFST). He previously led WellCare Health Plans as CEO, delivering strong performance in revenue and profit margins before its acquisition by Centene Corporation.

Dr. McFarland contributes more than 40 years of veterinary healthcare expertise, including 11 years in senior leadership at Zoetis, Inc. and previous roles at Pfizer Animal Health. Greg Hartmann will remain on the board as a director, maintaining his investment in the company.

LifeStance Health Group (NASDAQ: LFST) reported strong Q1 2025 financial results, marking its first profitable quarter as a public company. Revenue increased 11% to $333.0 million, driven by higher visit volumes and improved revenue per visit. The company achieved a net income of $0.7 million, compared to a net loss of $21.1 million in Q1 2024. The clinician base grew 10% to 7,535, with visit volumes increasing 10% to 2.1 million. Adjusted EBITDA rose 25% to $34.6 million. LifeStance maintained its full-year 2025 guidance, expecting revenue between $1.40-1.44 billion and Adjusted EBITDA of $130-150 million. The company ended Q1 with $134.3 million in cash and $276.3 million in net long-term debt.

LifeStance Health Group (NASDAQ: LFST), a major outpatient mental health care provider, has scheduled its first quarter 2025 earnings release and conference call. The company will release Q1 2025 earnings before market opening on Wednesday, May 7, 2025, followed by a live earnings conference call at 8:30 a.m. Eastern Time.

Investors can participate by dialing 1-800-715-9871 (domestic) or 1-646-307-1963 (international) using conference ID 6060781. A real-time audio webcast will be available through the Events and Presentations section of LifeStance's Investor Relations website, with related materials posted before the call. A replay will be accessible afterward on the same platform.

LifeStance Health released a survey revealing concerning trends in social media's impact on mental health self-diagnosis. The study found that 29% of Americans self-diagnose mental health conditions based on social media content, with only 47% of these individuals consistently seeking professional guidance.

The survey highlighted that 54% of respondents encounter mental health misinformation weekly on social media, while 23% seek mental health advice on these platforms. Among generations, Gen Z (50%) and millennials (38%) lead in self-diagnosis rates.

Key findings show 26% of respondents check social media within five minutes of waking up, and 76% find the idea of a digital detox appealing. The study also revealed that 40% of respondents frequently encounter clinical terms like "trauma" and "narcissist" on social media, with 32% reporting that such content has led them to question their relationships.

LifeStance Health Group (Nasdaq: LFST) announced significant leadership changes, with Dave Bourdon appointed as the new CEO effective March 3, succeeding Ken Burdick who will transition to Executive Chairman. Bourdon, who joined as CFO in 2022, brings over two decades of healthcare and mental health industry experience.

Ryan McGroarty, with 25 years of healthcare experience including 15 years in CFO roles, will become the new Chief Financial Officer effective March 17. Under Burdick's leadership since September 2022, LifeStance has met or exceeded expectations for nine consecutive quarters.

Bourdon previously served as CFO of Magellan Health and held positions at Cigna, while McGroarty comes from Help at Home where he served as CFO and previously held multiple CFO roles at Cigna.

LifeStance Health Group (NASDAQ: LFST) reported strong financial results for Q4 and full year 2024. Full-year revenue grew 19% to $1.251 billion, while Q4 revenue increased 16% to $325.5 million.

Key highlights include:

• Clinician base grew 12% to 7,424, adding 779 clinicians in 2024
• Visit volumes rose 15% to 7.9 million for the full year
• Generated $107.3 million in operating cash flow
• Adjusted EBITDA doubled to $119.7 million
• Free Cash Flow reached $85.7 million

For 2025, LifeStance projects revenue between $1.40-1.44 billion and Adjusted EBITDA of $130-150 million. Q1 2025 guidance expects revenue of $320-340 million.

LifeStance Health Group (NASDAQ: LFST), a major provider of outpatient mental health care services, has announced it will release its fourth quarter and full year 2024 earnings report before market opening on Thursday, February 27, 2025.

The company will host a live earnings conference call at 8:30 a.m. Eastern Time on the same day. Investors can participate by dialing 1-800-715-9871 (domestic) or 1-646-307-1963 (international) using conference ID 4372752. A live audio webcast will be available through the Events and Presentations section of LifeStance's Investor Relations website, where related materials will be posted before the call. A replay will be accessible afterward on the same platform.

LifeStance Health Group reported strong Q3 2024 results with revenue increasing 19% to $312.7 million. The company's clinician base grew 13% to 7,269, with visit volumes up 15% to 2.0 million. Net loss improved significantly to $6.0 million from $61.6 million in Q3 2023. Adjusted EBITDA more than doubled to $30.7 million. The company raised its full-year 2024 guidance, now expecting revenue between $1.228-1.248 billion and Adjusted EBITDA of $105-115 million. Cash flow from operations reached $44.9 million for the first nine months of 2024.